Form 4: Intellia Therapeutics Director Cohen Fred E. Reports Stock Grant and Option Award

Director Fred E. Cohen reports acquisition of 7,737 shares of common stock and an option to purchase 11,515 shares of Intellia Therapeutics.

Summary

• On June 12, 2024, Fred E. Cohen, a director of Intellia Therapeutics, Inc., reported changes in beneficial ownership of the company's securities.
• Cohen acquired 7,737 shares of common stock through a grant of restricted stock units, priced at $0.00.
• Following this transaction, Cohen directly owns 49,453 shares of Intellia common stock.
• Cohen was also granted an option to purchase 11,515 shares of common stock at an exercise price of $25.85, expiring on June 11, 2034.
• The stock option vests fully on the earlier of the first anniversary of the grant date or the date of the next annual meeting of stockholders.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive. The grant of stock options and restricted stock units suggests confidence in the company's future, but it's a routine transaction.

Positives

• The grant of restricted stock units and stock options to a director signals confidence in the company's future performance.

Future Outlook

The vesting of the stock option is contingent upon the earlier of the first anniversary of the grant date or the date of the next annual meeting of stockholders, indicating a performance-based incentive.

Industry Context

This filing is a routine disclosure of stock ownership changes by a company insider, which is common in the biotechnology industry.

Comparison to Industry Standards

• Stock option grants and restricted stock units are common forms of compensation for directors and executives in biotech companies like Intellia Therapeutics.
• Comparable companies such as CRISPR Therapeutics and Editas Medicine also utilize similar equity-based compensation strategies to align the interests of management and shareholders.
• The vesting schedules and exercise prices are generally in line with industry standards for incentivizing long-term performance.

Stakeholder Impact

• The transaction has a minor positive impact on shareholders as it aligns the director's interests with the company's long-term success.

Key Dates